The use of the CAR T-cell therapy Kymriah (tisagenlecleucel) was effective with manageable side effects in patients with relapsed/refractory B-cell acute lymphoblastic leukemia regardless of whether patients were children or young adults, according to registry data. Findings from this registry were presented at the 2021 ASH Annual Meeting & Exposition
NEW YORK and SOMERSET, N.J., Dec.
WASHINGTON, Dec. 11, 2021 /PRNewswire/ -- Three studies being presented during the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition throw a spotlight on novel approaches to screening for and treating blood diseases, as well as an unexpected, potential association between a blood abnormality and Alzheimer's disease. The first study demonstrates how the use of high-sensitivity screening techniques for the early detection of blood abnormalities may identify people at high risk for multiple myeloma earlier especially Black patients and those with a first-degree relative with the disease giving them more timely access to treatment.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today presented a trial-in-progress poster for the companys Phase 1/2 CEDAR trial for GPH101, an investigational therapy designed to directly correct the genetic mutation responsible for sickle cell disease (SCD)
NEW YORK and SOMERSET, N.J., Dec. 7, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc
Significance The recently introduced RNA velocity methods, by leveraging the intrinsic RNA splicing process, have shown their unique capability of identifying the directionality of the cell differentiation trajectory.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S.
During development, unspecialised cells (stem cells) contribute to the formation of the body.
The Adult Stem Cells market report covers the key trends overseeing the industry growth across the regional contributors.
NEW YORK, Dec. 2, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that biomarker data on NurOwn will be presented at the 32nd International Symposium on ALS/MND, to be held virtually7-10 December 2021.
Recent Comments